Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

This poster focuses on the applications in research of RTKs and featured RTK products that Sino Biological offers ...

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel ...

The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...

Monoclonal antibodies (mAbs ... and pharmacokinetics of an inhaled antibody therapy for COVID-19. They developed IN-006, a reformulation of regdanvimab, which is an IV-dosed mAb targeting the ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

With an increasing understanding of the underlying pathogenetic mechanisms and identification of specific therapeutic targets, monoclonal antibody treatment has been an ideal strategy for inducing ...

Antibodies are a successful class of therapeutic agents ... Following the success of the first generation of monoclonal antibody blockbusters, second-generation antibodies were recently approved.

Patients treated with monoclonal antibodies directed against ... diseases should be monitored in patients receiving therapeutic antibodies. You have full access to this article via your institution.